RXRX

Recursion Pharmaceuticals (RXRX) ended trading at $3.66, up 1.39% and outperforming the S&P 500's 0.28% gain. However, the stock has declined 9.07% over the past month, underperforming the Medical sector.

The company is expected to report improved EPS of -$0.24 (up 33.33% YoY) and revenue of $8.42 million (up 62.57% YoY), though full-year estimates show declining revenue of -42.66%. RXRX currently holds a Zacks Rank of #3 (Hold) with a slight 0.72% downward revision to consensus EPS estimates over the past month.

Recursion Pharmaceuticals (RXRX) fell 8.03% in the latest trading session, significantly underperforming the S&P 500's 0.06% decline. Despite a 36.25% gain over the past month, the stock has received a Zacks Rank #4 (Sell) rating.

The company faces headwinds with consensus EPS estimates revised 2.17% lower over the past month, though revenue projections show growth. The biotech sector itself ranks in the bottom 33% of industries.

Recursion Pharmaceuticals (RXRX) declined 3.14% to $4.63 on October 6, 2026, underperforming the broader market which gained modestly. Despite a strong 31.68% monthly gain, the stock fell as the S&P 500 rose 0.58%.

The company is expected to report an EPS of -$0.24 with revenue of $8.42 million, showing improvement year-over-year. RXRX holds a Zacks Rank #3 (Hold) rating with recent downward EPS estimate revisions.

Tempus AI (TEM) is strengthening its precision medicine presence through multiple strategic collaborations, including support for Moderna and Merck's cancer therapy commercialization and an extended data partnership with Recursion Pharmaceuticals through 2029. However, TEM's stock has underperformed the industry by 30.6% over the past year and trades at a premium valuation of 6.73X forward P/S versus the industry average of 4.90X, with the stock currently rated a Hold.